The initial symptoms are difficult to distinguish from other infectious illnesses, particularly flu-like illnesses. Symptoms usually progress quickly to a severe illness, often within 24 hours.

• Infants may have: a more gradual onset than adults, fever, cry, appear unsettled, feed poorly, vomit, be sleepy or hard to wake, dislike bright light, or have a rash or spots. They may have a bulging fontanelle.
• Older children and adults may have: a fever, malaise, nausea, vomiting, muscle aches and pains, drowsiness, headache, dislike of bright light, neck stiffness, or have a rash or spots.
• Individuals may also present with atypical symptoms, including gastrointestinal symptoms, pneumonia, septic arthritis, endocarditis, epiglottitis or supraglottitis.

Almost 80% of cases will develop a rash that does not blanch (become pale/go white) when pressed on. This type of rash is often a late sign of infection.

‍

Prompt diagnosis, early administration of injected antibiotic to patients suspected of having meningococcal infection and immediate admission to the hospital may help to decrease the risk of permanent damage and death.

• In New Zealand, infants and children aged under 5 years and adolescents aged 15–19 years have an increased risk of meningococcal disease. Māori, particularly infants aged under 1 year, and Pacific peoples have a higher risk of meningococcal disease than other ethnic groups. Over 2018–2019, a high rate of group B and groups C, Y and W disease cases were also seen in young adults aged 20—29 years.
• Exposure to tobacco smoke, binge drinking, or having another respiratory infection, e.g. influenza.
• Living in close proximity to others, e.g. in a crowded household, at boarding school, in university halls of residence, group accommodation or long-term institutional care.
• Being in a household or other close contact of someone carrying the bacteria or with the disease, e.g. those who have been intimate, or infants and children attending an early childhood education centre.
• Having a medical condition or receiving treatment that affects the immune system, e.g. the person has had their spleen removed, or taking disease modifying immunosuppressive medication.
• Age and ethnicity.

If meningococcal bacteria pass into the blood, the disease usually progresses very quickly. A person with meningococcal disease may develop:

• Meningitis (inflammation of the membranes around the brain)
• Septicaemia (blood infection)
• Pneumonia (lung infection)

One to two people out of every ten who survive meningococcal disease have long term complications, such as extensive skin scarring, amputation of limbs and extremities, hearing loss, seizures or brain injury

Even when the disease is identified and treated early 1–2 people in 10 will die.

‍

The risk of infection for household contacts of a person with the disease is highest during the first seven days and may persist for many weeks. Preventive antibiotics should be administered to close contacts as soon as possible, preferably within 24 hours of identification of the person with meningococcal disease.

During an outbreak, a meningococcal immunisation programme may be commenced for those in the highest risk groups if a vaccine is available. Meningococcal conjugate vaccines reduce the number of people carrying N. meningitidis in the back of their throat thereby reducing the spread of the bacteria around the community. This contributes to ‘herd immunity’ while protecting the individual from invasive disease.

Vaccines that protect against meningococcal disease have been available since the 1970s but none protect against all the groups that cause disease. There have been vaccines against the groups A, C, Y and W for more than 20 years but it has taken much longer to develop vaccines that protect against the different types of meningococcal group B. A fact sheet about meningococcal vaccines can be downloaded from the Resources section on this page.